Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$20.56-0.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SNDX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | 252.0 | 172.4 | 23.7 | 0.0 | 0.0 | 139.7 | 1.5 | 1.5 | 1.5 | 2.1 | 1.2 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 2.1 | 1.2 |
| Operating Expenses & Income | |||||||||||
| Selling, General & Admin | — | 179.7 | 120.9 | 66.9 | 33.3 | 25.2 | — | — | — | — | — |
| R&D Expenses | 261.8 | 258.8 | 241.6 | 163.0 | 118.5 | 88.2 | 50.4 | 43.0 | 60.1 | 48.2 | 31.7 |
| Operating Income | (194.2) | (273.1) | (339.7) | (230.0) | (151.8) | 26.2 | (71.4) | (57.5) | (75.9) | (62.0) | (43.8) |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | 0.0 | 4.9 | 0.2 | 3.1 | 1.9 | 2.4 | — | — | — | — |
| Interest & Investment Income | 16.9 | 22.7 | 26.1 | 21.2 | 5.9 | 0.4 | 0.8 | — | — | — | — |
| Net Interest Expenses | — | — | — | (21.0) | (2.7) | 1.5 | 1.5 | — | — | — | — |
| Other Non-Operating Income / Expenses | (26.6) | (12.3) | 20.9 | 20.6 | 2.4 | (1.3) | (1.7) | 1.5 | 1.9 | 1.2 | (0.7) |
| Income Tax Expense | — | 0.4 | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||
| Net Income | (220.7) | (285.4) | (318.8) | (209.4) | (149.3) | 24.9 | (73.2) | (56.0) | (74.0) | (60.8) | (44.5) |
| Per Share | |||||||||||
| Basic EPS | (2.48) | (3.29) | (3.72) | (2.98) | (2.46) | 0.48 | (1.87) | — | — | — | — |
| Diluted EPS | (2.48) | (3.29) | (3.72) | (2.98) | (2.46) | 0.46 | (1.87) | — | — | — | — |
| Revenue per Share | 2.83 | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 89.0 | 86.6 | 85.6 | 70.4 | 60.8 | 52.1 | 41.3 | — | — | — | — |
| Diluted Weighted Avg Shares | 89.0 | 86.6 | 85.6 | 70.4 | 60.8 | 53.6 | 41.3 | — | — | — | — |
| Supplemental | |||||||||||
| EBIT | (194.2) | (273.1) | (339.7) | (230.0) | (151.8) | 26.2 | (71.4) | (57.5) | (75.9) | (62.0) | (43.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.